Cingulate Inc. Reports Second Quarter 2026 Financial Results and Provides Update on CTx-1301 CMC Progress Towards NDA Resubmission and Commercial Readiness
Cingulate Inc. reported its Q2 2026 financial results, highlighted progress on the CMC requirements for resubmitting its NDA for CTx-1301, a next-generation ADHD treatment candidate, and detailed preparations for commercialization pending FDA approval. The company strengthened its intellectual property portfolio with a new patent for CTx-1301 and i…